Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

Pharma companies must balance demand for new drugs while facing reduced R&D spending.

Creating Innovation Nodes to Meet Unmet Medical Needs

Contamination is almost always related to human error and there is a clear drive to reduce human implications in aseptic operations. This can be achieved in multiple ways.

Avoiding Contamination Risks in Aseptic Processes

On Sept. 27, 2011, FDA sent Genentech a Form 483 listing several violations at the company's South San Francisco, California, plant. The violations included problems with investigations into batch failures, inappropriate equipment design, and insufficient protection against contamination. FDA visited the plant, which produces the cancer drug Avastin, 13 times in September 2011 and made four observations.

FDA Notifies Genentech of Violations at Avastin Plant

Small drug companies with hopes of achieving $1 billion in sales can pursue various strategies.

Growth for Small Pharma

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

Biosimilar manufacturers need better expression systems and analytical tools to compete.

Biosimilars' Technology Needs

The authors discuss the analysis of the resulting data, focusing on methods for the calculation of mass median aerodynamic diameter, one of the metrics routinely used for comparative testing.

Inhaled Product Characterization

The future, and increasingly the present, for aseptic operations is isolated robotics. Companies that wish to gain competitive advantages in their operations are stepping up and taking notice.

Isolated Robotics: The Future of Aseptic Operations

EMA released two concept papers for consultation that address the need to revise existing guidelines on biosimilar medicines and influenza vaccines.

EMA Invites Feedback on Biosimilar and Vaccine Concept Papers

Average deal size and amounts invested increased in the second quarter, but totals trail funding of last year.

Biotech Venture Funding Slips Below 2010 Levels

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.